Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Safety of SGLT2 inhibitors in active cancer patients: Rationale and study design of TOSCA trial
Anno:
2024
Background: SGLT2 inhibitors have dramatically improved the outcome of heart failure patients with both preserved (HFpEF), mildly reduced (HFmrEF) and reduced (HFrEF) ejection fraction. Cancer patients have been excluded (or not enrolled) from pivotal trials so data on safety in such population are lacking. We aimed to collect evidence…
Leggi di più
Atrial fibrillation and cardiotoxicity: is transcatheter ablation an effective strategy?
Anno:
2024
Atrial fibrillation (AF) is the most commonly cardiac arrhythmia in clinical practice with an incidence of about 1.5-2% in the general population, rising to 20% in cancer patients. The use of antiarrhythmics in patients undergoing chemotherapy, besides being less effective in maintaining sinus rhythm, leads to an increase in…
Leggi di più
A TAKOTSUBO SYNDROME TRIGGERED BY HYPOCALCEMIA: THE IMPORTANCE OF ELECTROLYTE BALANCE IN CANCER PATIENTS
Anno:
2024
Introduction: Takotsubo Syndrome (TTS) is characterized by a transient left ventricle (LV) systolic dysfunction usually occurring in postmenopausal women after intense physical or emotional stress. Case report: a 75-year-old female patient without a history of heart disease was admitted to our hospital for sudden onset of painful muscle spasms…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram